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Alzheimer’s & Dementia 10 (2014) S92-93Preface*As our population ages, functional decline and disability
are largely due to two related processes: cognitive decline
leading to dementia and physical decline. The costs related
to these problems are already huge and rapidly growing, lead-
ing to major social, political, and economic costs that must be
addressed by our society. This special issue ofAlzheimer’s and
Dementia focuses on one important aspect of the overall prob-
lem: cognitive decline and dementia in soldiers and veterans.
The overall goal of this special issue concerning military
risk factors for cognitive decline, Alzheimer’s disease, and de-
mentia is twofold: first, to provide, in one place, much of the
currently available evidence concerning thevarious risk factors
and exposures that are associated with cognitive decline, Alz-
heimer’s disease, and dementia in soldiers and military veter-
ans and second, to give greater evidence and arouse interest
in this issue. To date, there has been too little recognition that
soldiers and military veterans are a special population with a
unique set of risks and exposures that differentiate them from
the general civilian population. The Veterans Administration
provides the largest single health-care organization in the
United States, yet the great majority of Alzheimer’s disease
clinical trials are not conducted at VA Medical Centers, in
part because of the perceived high rate of comorbidities in vet-
erans. When, in the future, disease-modifying treatments for
Alzheimer’s disease become available, the Veterans Adminis-*This is an open access article under the CC BY-NC-ND license (http://
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critical that clinical Alzheimer’s disease trials be conducted
at Veterans Administration Medical Centers, to determine the
efficacy of such treatments in the veteran population.
This special issue also represents the coming together of
several previously separate streams of neuroscience.
Posttraumatic stress disorder
Studies of posttraumatic stress disorder (PTSD) have
been conducted by psychiatrists for many years, and more
than a decade ago, reduced volume of the hippocampus in
such subjects was reported. Further studies showed impaired
cognition in some veterans with PTSD, leading to the appre-
ciation that PTSD may be a risk factor for cognitive decline,
Alzheimer’s disease, and other conditions that affect cogni-
tion especially vascular disease. This issue is reviewed in
several articles within this issue.Traumatic brain injury
It has been long recognized that traumatic brain injury
(TBI) can lead to cognitive impairment. Repeated TBI
may lead to “dementia pugilistica” now termed chronic trau-
matic encephalopathy, which is associated with deposition
of tau protein. Furthermore, TBI has been widely reported
as a risk factor for the development of dementia due to Alz-
heimer’s disease pathology. Several articles in this issue deal
with these topics as well.
Exposures either unique to, or more common in, the
soldier and veteran population include Agent Orange, sarin,
pesticides, various petroleum products, and others that have
already been reported to be associated with Parkinson’s dis-
ease and other neurodegenerative conditions. Exposure to
tobacco smoke increases risk for lung, heart, and brain dis-
eases associated with cognitive impairment.
Finally, it is generally accepted that common conditions
including hypertension, metabolic syndrome, diabetes, and
obesity are associated with cardiovascular and cerebrovas-
cular diseases, which clearly contribute to cognitive impair-
ments, often associated with neurodegenerative diseases
such as Alzheimer’s disease and Parkinson’s disease.
In conclusion, this special issue brings together new data
and reviews by a variety of experts, leading to a common
theme: soldiers and veterans are a unique population withimer’s Association.
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ease, and dementia. The Department of Defense, Depart-
ment of Veterans Affairs, and the National Institutes of
Health must work with industry, philanthropy, and academe
to develop a comprehensive approach for effective treatment
and prevention of Alzheimer’s disease and associated condi-
tions, thus preventing functional disability due to cognitive
impairment.We, as a society, owe this to “thosewho served.”Michael W. Weiner*
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